School of Biosciences and Veterinary Medicine, University of Camerino, Via Gentile III da Varano, 62032 Camerino, Italy.
NanoDelivery Lab, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, 00161 Rome, Italy.
Mol Pharm. 2023 Nov 6;20(11):5247-5253. doi: 10.1021/acs.molpharmaceut.3c00479. Epub 2023 Oct 2.
The integration of the lipid nanoparticle (LNP)-protein corona as a pioneering approach for the development of vaccines against the present and future SARS-CoV-2 variants of concern marks a significant shift in the field. This concept holds great promise, offering a universal platform that can be adaptable to combat future pandemics caused by unknown viruses. Understanding the complex interactions among the protein corona, LNPs, and receptors is crucial for harnessing its potential. This knowledge will allow optimal vaccine formulations and improve their effectiveness. Safety assessments are essential to ensure suitability for human use, compliance with regulatory standards, and rigorous quality control in manufacturing. This transformative workflow requires collaborative efforts, expanding our foundational knowledge and translating advancements from the laboratory to clinical reality. The LNP-protein corona approach represents a paradigmatic shift with far-reaching implications. Its principles and insights can be leveraged beyond specific applications against SARS-CoV-2, enabling a universal platform for addressing viral threats, cancer, and genetic diseases.
脂质纳米颗粒(LNP)-蛋白冠的整合作为开发针对当前和未来 SARS-CoV-2 关注变体疫苗的开创性方法,标志着该领域的重大转变。这一概念具有巨大的潜力,提供了一个通用平台,可以适应由未知病毒引起的未来大流行。了解蛋白冠、LNP 和受体之间的复杂相互作用对于利用其潜力至关重要。这方面的知识将允许优化疫苗配方并提高其效果。安全性评估对于确保适合人类使用、符合监管标准以及在制造过程中的严格质量控制是必不可少的。这种变革性的工作流程需要协作努力,扩展我们的基础知识,并将实验室的进展转化为临床现实。LNP-蛋白冠方法代表了一种具有深远影响的范式转变。其原则和见解不仅可以针对 SARS-CoV-2 应用,还可以在超越特定应用的基础上,为应对病毒威胁、癌症和遗传疾病提供一个通用平台。